Pharmaceutical companies are now racing to find drugs, vaccines, and other treatments for SARS-CoV-2 (COVID-19) pandemic while still researching other conditions. However, the risks and benefits of these drugs need to be studied, detected, and ascertained in clinical trials (before they are approved by regulatory authorities like the FDA) and after the drug is released where patients and healthcare practitioners report other side effects (if any).
Obviously, the benefits need to outweigh the possible risks or side-effects. In other words, the role of pharmacovigilance reporting can’t be overlooked.
Windward can make this reporting and sharing process swift and accurate. Even an individual drug safety specialist in your company can create templates needed for the report (without any coding knowledge) and generate dozens of reports in just a few clicks.
As a drug company, you will do thousands of tests and studies on drugs before one (or a few) of them get through the approval process. As part of this course, you need to come up with pharmacovigilance reports during clinical trials, so you can share them with other drug safety specialists in the company and external regulatory bodies to speed up the approval process.
With Windward’s reporting automation software, you can ensure these reports are accurate despite reams of data present in them. The best part about this reporting software is it can integrate with a wide range of data sources and you can create reports right within familiar platforms like MS Office.
We understand due to the globalization of drug-distribution (subsequent availability of a drug to millions of people) and other broader safety issues (overdoses, irrational drug usage among others), your pharmacovigilance reporting system needs to be extensive and better prepared.
Windward’s robust reporting solution can play a crucial role in generating reports that help better communicate and collaborate between key partners in your company’s pharmacovigilance system.
So as a drug company, you can constantly monitor and stay on top of any adverse reaction reports and other safety concerns due to the medicines you develop. Besides, you can encourage engaging surveillance of specific drug safety concerns through case-control studies and reports. You can ensure the rapid availability of any adverse reaction reports and data that may be relevant at the local or international level by using advanced reporting software.
This way, you can mitigate any potential disasters that may arise due to the drug safety crisis while at other times assess the reports to prevent any premature withdrawal of safe and effective drugs from the market.